Compare Novo Nordisk A/S (NVO) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oklo Inc — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Oklo Inc trades at $42.64 (market cap $7.92B). The key difference: Novo Nordisk A/S is far larger — about 25.1× Oklo Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| NVO | OKLO | |
|---|---|---|
Market Cap | $198.57B | $7.92B |
Sector | Health | Technology |
52-Week High | $63.98 | $174.14 |
52-Week Low | $35.29 | $36.84 |
Enterprise Value | $213.37B | $5.46B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
OKLO trades at $43.31, up 4.94% in the last 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock shows significant losses with a net income margin of -12,625.54% and negative cash flow from operations, but strong financing inflows support growth investments. Recent news highlights progress in small modular reactor projects amid sector volatility, with a 52-week low of $36.61 indicating potential support levels.
Outlook: Wall Street consensus is bullish with a $71.58 price target, driven by AI power demand and nuclear energy tailwinds. Risks include project delays, high cash burn, and lack of profitability. The stock offers high growth potential but requires tolerance for execution risk and extended timelines to commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
